Reduced Folate Carrier Protein
"Reduced Folate Carrier Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitously expressed folic acid transporter that functions via an antiporter mechanism which is coupled to the transport of organic phosphates.
| Descriptor ID |
D058978
|
| MeSH Number(s) |
D12.776.157.530.450.074.500.299.750 D12.776.157.530.450.162.359 D12.776.157.530.937.622 D12.776.543.550.190.608 D12.776.543.585.450.074.500.224.750 D12.776.543.585.450.162.359 D12.776.543.585.937.743 D23.050.301.500.600.813 D23.050.705.552.600.663
|
| Concept/Terms |
Reduced Folate Carrier Protein- Reduced Folate Carrier Protein
- SLC19a1 Transporter
- Transporter, SLC19a1
- Folate Transporter 1
- Transporter 1, Folate
- SLC19a1 Protein
- Protein, SLC19a1
- Reduced Folate Carrier
- Carrier, Reduced Folate
- Folate Carrier, Reduced
- Solute Carrier Family 19, Member 1
|
Below are MeSH descriptors whose meaning is more general than "Reduced Folate Carrier Protein".
Below are MeSH descriptors whose meaning is more specific than "Reduced Folate Carrier Protein".
This graph shows the total number of publications written about "Reduced Folate Carrier Protein" by people in this website by year, and whether "Reduced Folate Carrier Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Reduced Folate Carrier Protein" by people in Profiles.
-
Liu T, Singh R, Rios Z, Bhushan A, Li M, Sheridan PP, Bearden SE, Lai JCK, Agbenowu S, Cao S, Daniels CK. Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells. Cancer Lett. 2015 Feb 01; 357(1):231-241.
-
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 01; 28(4):614-9.
-
Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, Manara MC, Scotlandi K, Picci P, Serra M. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol. 2003 Sep; 82(9):483-93.